|Bid||100.75 x 800|
|Ask||100.84 x 800|
|Day's Range||98.32 - 101.08|
|52 Week Range||80.24 - 117.56|
|Beta (3Y Monthly)||0.69|
|PE Ratio (TTM)||96.76|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.
President & CEO of Haemonetics Corp (NYSE:HAE) Christopher Simon, sold 57,587 shares of HAE on 05/13/2019 at an average price of $94.51 a share.
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.
PerkinElmer (PKI) is gaining steadily from its core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Haemonetics Corp NYSE:HAEView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for HAE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting HAE. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.00 billion over the last one-month into ETFs that hold HAE are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Haemonetics (HAE) delivered earnings and revenue surprises of 10.91% and -0.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Braintree, Massachusetts-based company said it had profit of 40 cents per share. Earnings, adjusted for one-time gains and costs, came to 61 cents per share. The results beat Wall Street expectations. ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2016 Chris Simon was appointed CEO of Haemonetics Corporation (NYSE:HAE). This analysis...
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Investors are always looking for growth in small-cap stocks like Haemonetics Corporation (NYSE:HAE), with a market cap of US$4.5b. However, an important fact which most ignore is: how financially healthy is the business...
Haemonetics' (HAE) Plasma arm steadily witnesses solid growth in the fiscal third quarter on 16% revenue rise at constant currency.
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medidata Solutions acquired Waltham-based Shyft Analytics in June, and plans to hire hundreds of employees with a move to downtown Boston.
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.